GleamWall
中文EN

BBOT BridgeBio Oncology Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1869105 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.2%
TTM EPS YoY100.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-46.4%
ROA-41.3%
ROIC (approx.)-116.1%
Asset turnover—

Leverage & solvency

Liabilities / assets15.3%
Debt / equity0.00x
Current ratio4.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$29.59M$49.23M$39.80M$38.07M$35.05M$27.44M$20.64M$19.54M
SG&A expense$7.89M$10.96M$6.38M$5.33M$14.13M$2.65M$2.50M$2.34M
Operating income-$37.49M-$60.19M-$46.18M-$43.41M-$49.18M-$30.09M-$23.14M-$21.88M
Income tax$0$0—$0$0$0$0$0
Net income-$34.18M-$56.45M-$42.11M-$38.80M-$44.76M-$28.43M-$22.05M-$19.69M
EBITDA-$37.39M-$60.09M-$46.10M-$43.32M-$49.08M-$29.99M-$23.08M-$21.83M
EPS (basic)-0.43-705.20-526.11—-1.03-566.46-54.23—
EPS (diluted)-0.43-705.20-526.11—-1.03-566.46-54.23—
Weighted avg. shares (diluted)80.18M80.05M80,032—43.49M50.20M406,723—
Balance sheet
Cash & equivalents$76.48M$54.06M$52.66M$373.69M$408.87M$31.65M$26.35M$30.98M
Short-term investments$117.39M$171.65M$199.62M$51.77M$59.54M——$124.78M
Current assets$208.33M$242.38M$266.50M$432.40M$476.01M$876,779$1.24M$158.69M
PP&E, net$815,000$878,000$938,000$956,000$827,000——$490,000
Total assets$346.22M$376.71M$417.65M$448.38M$484.79M$197.39M$195.68M$164.30M
Current liabilities$51.03M$51.63M$43.26M$35.04M$35.71M$2.63M$1.87M$19.58M
Total liabilities$52.84M$53.59M$45.37M$37.28M$38.09M$8.15M$7.39M$19.58M
Shareholders' equity$293.39M$323.11M$372.28M$411.10M$446.70M-$227.73M-$200.03M-$178.64M
Shares outstanding80.23M80.12M80.09M79.99M79.20M——28,415
Cash flow statement
Operating cash flow-$28.36M-$44.36M-$35.92M-$42.23M-$70.63M-$23.29M-$19.60M-$15.04M
Capital expenditure$13,000$47,000$24,000$73,000$140,000$231,000$162,000$10,000
Free cash flow-$28.38M-$44.41M-$35.94M-$42.31M-$70.77M-$23.52M-$19.76M-$15.04M
Investing cash flow$50.34M$45.73M-$285.41M$7.77M$40.55M$9.64M$15.37M$25.56M
Financing cash flow$442,000$37,000$295,000-$586,000$365.44M$18.96M-$404,000$52,000
Depreciation & amortization$100,000$100,000$74,000$84,000$100,000$100,000$54,000$52,000
Stock-based compensation$4.75M$7.23M$3.87M$2.95M$1.43M$875,000$627,000$587,000

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.